News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) to Buy $129.4M in Theravance, Inc. (THRX) Stock


11/29/2010 7:45:08 AM

San Francisco Business Times - by John Sailors -- GlaxoSmithKline PLC will buy about $129.4 million worth of stock in Theravance Inc. in a private placement, the companies said Monday.

London-based Glaxo (NYSE: GSK) agreed to buy 5.75 million shares for $22.50 each.

The purchase increases Glaxo's stake in South San Francisco-based Theravance (NASDAQ: THRX) to 19 percent.

The transaction is expected to close today.

Theravance is working with Glaxo to develop Relovair, an asthma treatment. The two companies began collaborating on the drug in 2002.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES